文献速递眼底病与葡萄膜炎

法瑞西单抗相关眼内炎症伴单纯疱疹病毒特征

Faricimab-Associated Intraocular Inflammation With Features of Herpes Simplex Virus.
PubMed 文献 · Am J Ophthalmol · 2025-02-25

单中心回顾性干预性病例系列报告5例(5眼)玻璃体腔注射法瑞西单抗后出现重度眼内炎症,4眼为新生血管性年龄相关性黄斑变性、1眼为糖尿病性黄斑水肿;所有患眼均表现为前房炎症、眼压升高及符合单纯疱疹病毒性角膜葡萄膜炎的特征,4例(80%)未恢复基线视力。

要点

  • 法瑞西单抗注射后中位5次(范围3-13次)出现眼内炎症,注射至症状发生平均间隔16.8天(范围1-35天)。
  • 所有患眼均有前房炎症和眼压升高(平均32.8±4.15 mmHg,范围28-38 mmHg),并呈现树枝状溃疡、角膜知觉减退和肉芽肿性角膜后沉着物等HSV特征。
  • 所有病例使用局部或全身激素,4例(80%)联用抗病毒治疗,炎症消退中位时间15.5天,4例(80%)未恢复基线视力。

核心结论

  • 本病例系列发现法瑞西单抗相关眼内炎症与病毒再激活特征之间存在此前未报告的关联。
  • 时间关系(包括提示迟发型超敏反应的发生模式)、一致的HSV特征及良好的抗病毒反应,提示可能机制与VEGF-A和Ang-2介导的眼部免疫监视改变有关。
  • 作者指出需进一步研究以确立因果关系,但临床医生在评估和治疗此类病例时应考虑病毒机制。

研究设计与样本

  • 单中心回顾性干预性病例系列。
  • 纳入2023年6月至2024年10月间因新生血管性年龄相关性黄斑变性(nAMD,n=4)或糖尿病性黄斑水肿(DME,n=1)接受玻璃体腔法瑞西单抗注射后发生重度眼内炎症的5例患者(5眼)。
  • nAMD患者既往平均接受17.75±9.18次抗VEGF注射(范围6-26次);DME患者既往接受7次阿柏西普注射和2次地塞米松植入物。
  • 法瑞西单抗前,3例患者正接受阿柏西普治疗,2例接受雷珠单抗生物类似药治疗。
  • 通过系统回顾随访预约和急诊就诊识别病例,必要时行光学相干断层扫描和荧光素血管造影检查。

主要发现

  • 炎症前法瑞西单抗注射次数中位数为5次(范围3-13次)。
  • 注射至症状发生平均间隔16.8天(范围1-35天)。
  • 所有患者均表现为前房炎症和眼压升高(平均32.8±4.15 mmHg,范围28-38 mmHg)。
  • 所有患者均呈现符合HSV角膜葡萄膜炎的特征,包括树枝状溃疡、角膜知觉减退和肉芽肿性角膜后沉着物。
  • 所有病例接受局部或全身激素治疗,4例(80%)同时接受抗病毒治疗;炎症消退中位时间15.5天,4例(80%)未恢复基线视力。

局限性

  • 原文指出需进一步研究以确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Faricimab-associated intraocular inflammation (IOI) is an emerging concern. We aimed to investigate clinical features, management, and outcomes of severe IOI following faricimab therapy, with particular attention to cases displaying features consistent with herpes simplex virus (HSV) involvement. DESIGN: Single-center retrospective interventional case series. SUBJECTS: Five patients (5 eyes) who developed severe IOI following intravitreal faricimab injection for neovascular age-related macular degeneration (nAMD, n = 4) or diabetic macular edema (DME, n = 1) between June 2023 and October 2024. The nAMD patients had received a mean of 17.75 ± 9.18 prior anti-VEGF injections (range 6-26 injections). The DME patient had previously received 7 aflibercept injections and 2 dexamethasone implants. Prior to faricimab, 3 patients were being treated with aflibercept and 2 with ranibizumab biosimilar. METHODS: Medical records were reviewed for clinical features, treatment approaches, and outcomes. Cases were identified through systematic review of follow-up appointments and urgent care presentations. When clinically indicated, additional investigations including optical coherence tomography and fluorescein angiography were performed. MAIN OUTCOME MEASURES: Best-corrected visual acuity (BCVA), intraocular pressure (IOP), anterior chamber (AC) inflammation, presence of keratic precipitates (KPs), vitreous cells, signs of viral reactivation, and treatment response. RESULTS: The median number of faricimab injections before inflammation was 5 (range 3-13). Mean interval between injection and symptom onset was 16.8 days (range 1-35). All patients presented with AC inflammation and elevated IOP (mean 32.8 ± 4.15 mmHg, range 28-38 mmHg). All patients demonstrated features consistent with HSV keratouveitis, including dendritic ulcers, reduced corneal sensation, and granulomatous KPs. Treatment included topical or systemic steroids in all cases, with 4 patients (80%) receiving concurrent antiviral therapy. Median time to inflammation resolution was 15.5 days. Four patients (80%) did not recover baseline vision. CONCLUSIONS: This case series identifies a previously unreported association between faricimab-associated IOI and features of viral reactivation. The temporal relationship including onset patterns suggestive of delayed hypersensitivity, alongside consistent HSV features and favourable antiviral response, suggests a possible mechanism linked to VEGF-A and Ang-2 mediated alterations in ocular immune surveillance. While further investigation is needed to establish causality, clinicians should consider viral mechanisms when evaluating and treating these cases.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Janmohamed IK, Salam MAU, Jamall O, et al. Faricimab-Associated Intraocular Inflammation With Features of Herpes Simplex Virus. Am J Ophthalmol. 2025. PMID: 40015591. doi:10.1016/j.ajo.2025.02.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。